Evading and overcoming AAV neutralization in gene therapy

Alliance for Regenerative Medicine, 2021, 19 Wang, 2019, Clinical translation of gene medicine, J. Gene Med., 21, 10.1002/jgm.3108 European Medicines Agency, 2018, 38 Lundstrom, 2018, Viral vectors in gene therapy, Diseases, 6, 42, 10.3390/diseases6020042 Kerr, 2005 Grieger, 2005, Adeno-associated virus as a gene therapy vector: vector development, production and clinical applications, 119 Lusby, 1980, Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA, J. Virol., 34, 402, 10.1128/jvi.34.2.402-409.1980 VandenDriessche, 2007, Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy, J. Thromb. Haemost., 5, 16, 10.1111/j.1538-7836.2006.02220.x Boutin, 2010, Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors, Hum. Gene Ther., 21, 704, 10.1089/hum.2009.182 Rabinowitz, 2019, Adeno-associated virus (AAV) versus immune response, Viruses, 11, 102, 10.3390/v11020102 Calcedo, 2013, Humoral immune response to AAV, Front. Immunol., 4, 341, 10.3389/fimmu.2013.00341 Ronzitti, 2020, Human immune responses to adeno-associated virus (AAV) vectors, Front. Immunol., 11, 670, 10.3389/fimmu.2020.00670 George, 2020, Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B, Mol. Ther., 28, 2073, 10.1016/j.ymthe.2020.06.001 Calcedo, 2011, Adeno-associated virus antibody profiles in newborns, children, and adolescents, Clin. Vaccine Immunol., 18, 1586, 10.1128/CVI.05107-11 Ferla, 2015, Prevalence of anti-adeno-associated virus serotype 8 neutralizing antibodies and arylsulfatase B cross-reactive immunologic material in mucopolysaccharidosis VI patient candidates for a gene therapy trial, Hum. Gene Ther., 26, 145, 10.1089/hum.2014.109 Stanford, 2019, Adenovirus-associated antibodies in UK cohort of hemophilia patients: a seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV 5 and AAV 8 neutralizing activity and antibodies in patients with hemophilia A, Res. Practice Thromb. Haemost., 3, 261, 10.1002/rth2.12177 Ivanova, 2009, Evaluation of the adeno-associated virus mediated long-term expression of channelrhodopsin-2 in the mouse retina, Mol. Vis., 15, 1680 Scallan, 2006, Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice, Blood, 107, 1810, 10.1182/blood-2005-08-3229 Jiang, 2006, Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy, Blood, 108, 3321, 10.1182/blood-2006-04-017913 Li, 2012, Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther., 19, 288, 10.1038/gt.2011.90 Gross, 2022, Overcoming the challenges imposed by humoral immunity to AAV vectors to achieve safe and efficient gene transfer in seropositive patients, Front. Immunol., 13, 10.3389/fimmu.2022.857276 Flotte, 2020, Revisiting the “new” inflammatory toxicities of adeno-associated virus vectors, Hum. Gene Ther., 31, 398, 10.1089/hum.2020.29117.trf Shieh, 2020, Re: “Moving forward after two deaths in a gene therapy trial of myotubular myopathy” by Wilson and Flotte, Hum. Gene Ther., 31, 787, 10.1089/hum.2020.217 Wilson, 2020, Moving forward after two deaths in a gene therapy trial of myotubular myopathy, Hum. Gene Ther., 31, 695, 10.1089/hum.2020.182 Kishimoto, 2022, Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’?, Expert Opin. Biol. Ther., 22, 1067, 10.1080/14712598.2022.2060737 Bennett, 2012, AAV2 gene therapy readministration in three adults with congenital blindness, Sci. Transl. Med., 4, 120ra115, 10.1126/scitranslmed.3002865 Mingozzi, 2013, Overcoming preexisting humoral immunity to AAV using capsid decoys, Sci. Transl. Med., 5, 194ra192, 10.1126/scitranslmed.3005795 Calcedo, 2009, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses, J. Infect. Dis., 199, 381, 10.1086/595830 Rapti, 2012, Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models, Mol. Ther., 20, 73, 10.1038/mt.2011.177 Bartel, 2012, Directed evolution of novel adeno-associated viruses for therapeutic gene delivery, Gene Ther., 19, 694, 10.1038/gt.2012.20 Maheshri, 2006, Directed evolution of adeno-associated virus yields enhanced gene delivery vectors, Nat. Biotechnol., 24, 198, 10.1038/nbt1182 Tse, 2017, Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion, Proc. Natl. Acad. Sci. U. S. A., 114, E4812, 10.1073/pnas.1704766114 Li, 2016, Development of patient-specific AAV vectors after neutralizing antibody selection for enhanced muscle gene transfer, Mol. Ther., 24, 53, 10.1038/mt.2015.134 Thwaite, 2015, AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy, Gene Ther., 22, 196, 10.1038/gt.2014.103 Mével, 2020, Chemical modification of the adeno-associated virus capsid to improve gene delivery, Chem. Sci., 11, 1122, 10.1039/C9SC04189C Lee, 2005, PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization, Biotechnol. Bioeng., 92, 24, 10.1002/bit.20562 Kelemen, 2016, A precise chemical strategy to alter the receptor specificity of the adeno-associated virus, Angew. Chem. Int. Ed. Engl., 55, 10645, 10.1002/anie.201604067 Yao, 2017, Site-specific PEGylated adeno-associated viruses with increased serum stability and reduced immunogenicity, Molecules, 22, 1155, 10.3390/molecules22071155 Yuan, 2022, Mitigating the immunogenicity of AAV-mediated gene therapy with an immunosuppressive phosphoserine-containing zwitterionic peptide, J. Am. Chem. Soc., 144, 20507, 10.1021/jacs.2c09484 Maguire, 2012, Microvesicle-associated AAV vector as a novel gene delivery system, Mol. Ther., 20, 960, 10.1038/mt.2011.303 Meliani, 2017, Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors, Blood Adv., 1, 2019, 10.1182/bloodadvances.2017010181 Collaud, 2019, Preclinical development of an AAV8-hUGT1A1 vector for the treatment of Crigler–Najjar syndrome, Mol. Ther. Methods Clin. Dev., 12, 157, 10.1016/j.omtm.2018.12.011 Penn, 2000, Post-transplant malignancy: the role of immunosuppression, Drug Saf., 23, 101, 10.2165/00002018-200023020-00002 Mingozzi, 2012, Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B, Mol. Ther., 20, 1410, 10.1038/mt.2012.84 Mingozzi, 2013, Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue, Gene Ther., 20, 417, 10.1038/gt.2012.55 Everly, 2012, The state of therapy for removal of alloantibody producing plasma cells in transplantation, Semin. Immunol., 24, 143, 10.1016/j.smim.2011.08.014 Shi, 2021, Efficacy of AAV8-hUGT1A1 with rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNS patients, Mol. Ther. Methods Clin. Dev., 20, 287, 10.1016/j.omtm.2020.11.016 Meliani, 2018, Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration, Nat. Commun., 9, 4098, 10.1038/s41467-018-06621-3 Sudres, 2012, MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV, Mol. Ther., 20, 1571, 10.1038/mt.2012.101 Moghadam, 2020, Synthetic immunomodulation with a CRISPR super-repressor in vivo, Nat. Cell Biol., 22, 1143, 10.1038/s41556-020-0563-3 Burgin, 1992, Serum IgG and IgM levels in new and regular long-term plasmapheresis donors, Med. Lab. Sci., 49, 265 Monteilhet, 2011, A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8, Mol. Ther., 19, 2084, 10.1038/mt.2011.108 Chicoine, 2014, Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery, Mol. Ther., 22, 338, 10.1038/mt.2013.244 Bertin, 2020, Capsid-specific removal of circulating antibodies to adeno-associated virus vectors, Sci. Rep., 10, 864, 10.1038/s41598-020-57893-z Orlowski, 2020, Successful transduction with AAV vectors after selective depletion of anti-AAV antibodies by immunoadsorption, Mol. Ther. Methods Clin. Dev., 16, 192, 10.1016/j.omtm.2020.01.004 Jordan, 2017, IgG endopeptidase in highly sensitized patients undergoing transplantation, N. Engl. J. Med., 377, 442, 10.1056/NEJMoa1612567 Ros-Gañán, 2022, Optimising the IgG-degrading enzyme treatment regimen for enhanced adeno-associated virus transduction in the presence of neutralising antibodies, Clin. Transl. Immunol., 11, 10.1002/cti2.1375 Leborgne, 2020, IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies, Nat. Med., 26, 1096, 10.1038/s41591-020-0911-7 Chu, 2021, Immunomodulation in administration of rAAV: preclinical and clinical adjuvant pharmacotherapies, Front. Immunol., 12, 858, 10.3389/fimmu.2021.658038 Russell, 2017, Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, Phase 3 trial, Lancet, 390, 849, 10.1016/S0140-6736(17)31868-8 Mendell, 2017, Single-dose gene-replacement therapy for spinal muscular atrophy, N. Engl. J. Med., 377, 1713, 10.1056/NEJMoa1706198 Ferreira, 2014, Immune responses to AAV-vectors, the Glybera example from bench to bedside, Front. Immunol., 5, 82, 10.3389/fimmu.2014.00082 Gougeon, 2021, Cell-mediated immunity to NAGLU transgene following intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome, Front. Immunol., 12, 10.3389/fimmu.2021.655478 Corti, 2014, B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study, Mol. Ther. Methods Clin. Dev., 1, 14033, 10.1038/mtm.2014.33